Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration
- PMID: 2468688
- PMCID: PMC303856
- DOI: 10.1172/JCI114047
Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration
Abstract
To better define the inflammatory infiltrates and kinetics of mediator release during the cutaneous late-phase reaction (LPR), we examined skin biopsies at 8 h, and skin chamber cell counts and mediator release for 12 h after antigen challenge. Compared with the control sites, the antigen-stimulated biopsy sites contained 14 times as many basophils (P less than 0.01) and six times as many eosinophils (P less than 0.001) with one to two fold more mononuclear cells (P less than 0.03) and neutrophils (P less than or equal to 0.01). Similar changes were found in the skin chambers. Although there were neutrophils in the control chamber, they were only twice as numerous in the antigen challenged site (P less than 0.01). Eosinophils were 35-fold (P less than or equal to 0.03) more prevalent in the antigen chamber than the control chamber for hours 8-12 and basophils were noted starting in the eighth hour and were 20-fold (P less than or equal to 0.03) more concentrated in the antigen chamber during the next 4 h. The mononuclear cells were not significantly different between antigen and control blisters. With respect to inflammatory mediators, there was an initial peak of histamine (13.2 +/- 2.9 ng/ml) in the blister fluid at 1 h. The level then fell to approximately 2 ng/ml, followed by a secondary rise starting at the eighth hour and increasing to 9.8 +/- 2.8 ng/ml by the twelfth hour. This secondary increase in histamine correlated significantly (r = 0.81, P less than 0.05) with the observed influx of basophils. PGD2 in the blister fluid rose to 371+/-25 pg/ml during the first 4 h and then slowly decreased to half this level during the last 4 h. Thus, the cutaneous LPR has been shown to manifest a secondary increase in histamine levels and a markedly specific increase in eosinophils and basophils with mediator release apparently being derived from the latter cells.
Similar articles
-
Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen.J Immunol. 1991 Jan 15;146(2):671-6. J Immunol. 1991. PMID: 1702812 Clinical Trial.
-
The relationship between infiltrating CD4+ lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man.J Immunol. 1988 Dec 15;141(12):4158-64. J Immunol. 1988. PMID: 2974055
-
The pattern and kinetics in human skin of erythema and mediators during the acute and late-phase response (LPR).J Allergy Clin Immunol. 1989 Nov;84(5 Pt 1):678-87. doi: 10.1016/0091-6749(89)90296-0. J Allergy Clin Immunol. 1989. PMID: 2478604 Clinical Trial.
-
Pathogenesis and pharmacologic modulation of the cutaneous late-phase reaction.Ann Allergy. 1993 Dec;71(6):578-84. Ann Allergy. 1993. PMID: 7505536 Review.
-
The role of basophils in allergic disease.Eur Respir J Suppl. 1996 Aug;22:126s-131s. Eur Respir J Suppl. 1996. PMID: 8871057 Review.
Cited by
-
Melittin-Carrying Nanoparticle Suppress T Cell-Driven Immunity in a Murine Allergic Dermatitis Model.Adv Sci (Weinh). 2023 Mar;10(7):e2204184. doi: 10.1002/advs.202204184. Epub 2023 Jan 13. Adv Sci (Weinh). 2023. PMID: 36638280 Free PMC article.
-
Effects of an Oral CRTh2 Antagonist (AZD1981) on Eosinophil Activity and Symptoms in Chronic Spontaneous Urticaria.Int Arch Allergy Immunol. 2019;179(1):21-30. doi: 10.1159/000496162. Epub 2019 Mar 15. Int Arch Allergy Immunol. 2019. PMID: 30879003 Free PMC article. Clinical Trial.
-
Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls.Dig Dis Sci. 1997 Feb;42(2):394-403. doi: 10.1023/a:1018886423475. Dig Dis Sci. 1997. PMID: 9052525
-
The Inhibitory Effects of Low-Dose Ionizing Radiation in IgE-Mediated Allergic Responses.PLoS One. 2015 Aug 28;10(8):e0136394. doi: 10.1371/journal.pone.0136394. eCollection 2015. PLoS One. 2015. PMID: 26317642 Free PMC article.
-
Efficacy and Safety of Diethylcarbamazine in Treatment of Allergic Rhinitis: A Double Blind Randomised Controlled Trial.Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):1169-1177. doi: 10.1007/s12070-020-02249-2. Epub 2020 Oct 31. Indian J Otolaryngol Head Neck Surg. 2022. PMID: 36452711 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources